Health Economics›Non-small cell lung cancer›Advanced or metastatic disease EGFR inhibitor-exposed

Advanced or metastatic disease EGFR inhibitor-exposed

Non-small cell lung cancer · 9 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 7 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carboplatin, Lazertinib, Pemetrexed, Amivantamab Variant #01 Partial	EGFR	R 598 573	21d	8.3 mo	—	13	R 7 781 447 PFS proxy	1
Carboplatin, Pemetrexed, Amivantamab Variant #01	EGFR	R 598 573	21d	8.9 mo	—	13	R 7 781 447 PFS proxy	2
Lazertinib and Amivantamab Variant #01 Partial	EGFR	R 426 311	28d	23.7 mo	—	26	R 11 084 073 PFS proxy	2
ABCP Variant #01	EGFR	R 62 322	21d	8.5 mo	—	13	R 810 191 PFS proxy	1
Afatinib and Bevacizumab Variant #01	EGFR	R 48 157	21d	—	—	—	—	—
Afatinib monotherapy Variant #01	EGFR	R 34 727	28d	11.0 mo	—	12	R 416 729 PFS proxy	4
Afatinib and Cetuximab Variant #01	EGFR	R 30 560	14d	—	—	—	—	—
Cisplatin and Pemetrexed Variant #01	EGFR	R 1 088	21d	5.5 mo	22.5 mo	8	R 8 701 PFS proxy	20
Carboplatin and Pemetrexed N/A - secondary systemic drug	EGFR	R 52	21d	5.6 mo	22.5 mo	9	R 469 PFS proxy	18

9 of 9 regimens shown